The cell-death activator gene
egl-1 ( egl eg g- l aying defective) encodes the most upstream component of the general cell-death machinery in C. elegans . An
egl-1 loss-of-function (lf) mutation prevents most if not all somatic cell death during development (1) . In contrast,
egl-1 gain-of-function (gf) mutations result in ectopic cell death: they cause the hermaphrodite-specific neurons (HSNs) to inappropriately undergo programmed cell death in hermaphrodites (2). These
egl-1 (gf) mutations are located in a TRA-1A binding site downstream of the
egl-1 transcription unit (3) . The characterization of these mutations revealed that the terminal global regulator of somatic sexual fate, TRA-1A ( tra , tra nsformer) (4) , represses
egl-1 transcription in the HSNs in hermaphrodites and thereby prevents these neurons from undergoing programmed cell death. It has been proposed that TRA-1A represses
egl-1 transcription by negatively regulating a cell-type specific factor, such as an HSN-specific activator of
egl-1 (3) . The identity of this factor, however, is still elusive. Lf mutations in the Hox gene
egl-5 cause the phenotypes expected for lf mutations in an HSN-specific activator of
egl-1 transcription: About 40% of the HSNs survive in
egl-5(
n945) males and in
egl-1(
n986gf ); egl­-5
(n945 ) hermaphrodites (5) . Using an
egl-1::gfp reporter construct, we are investigating whether HSN survival in these animals is due to the repression of
egl-1 transcription. We will also try to determine whether
egl-1 is a direct target of
egl-5 using various biochemical and molecular methods. In addition, we have identified potential cell-type specific transcriptional regulators of
egl-1 in a yeast one-hybrid screen using a 500 bp regulatory region (which is conserved between C. elegans and C. briggsae ) of the
egl-1 locus as bait. We narrowed down the binding sites of two candidates to fragments of about 125 bp and one candidate binds to the TRA-1A binding site. We have cloned the corresponding cDNAs to confirm our results in Electric-Mobility-Shift assays. Currently, we are studying the possible function of these candidates in vivo, using RNAi or existing mutants. 1. B. Conradt, H. R. Horvitz, Cell 93 , 519-29 (1998). 2. C. Trent, N. Tsung, H. R. Horvitz. (1983). Genetics 104 , 619-647 3. B. Conradt, H. R. Horvitz, Cell 98 , 317-27 (1999). 4. D. Zarkower, J. Hodgkin, Nucleic Acids Res 21 , 3691-8 (1993). 5. C. Desai, G. Garriga, S. L. McIntire, H. R. Horvitz, Nature 336 , 638- 46 (1988).